These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25052613)

  • 1. [Efficacy of FLAG as initial induction chemotherapy followed by autologous hematopoietic stem cell transplantation after IBu conditioning regimen in acute myeloid leukemia with FLT3 mutations].
    Wang B; Yang B; Dong W; Liu D; Ling Y; Cao X
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):653-5. PubMed ID: 25052613
    [No Abstract]   [Full Text] [Related]  

  • 2. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
    Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
    Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The clinical comparison of FLAG regimen versus IA regimen for newly diagnosed acute myeloid leukemia].
    Yang B; Cao XS; Wang B
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):141-3. PubMed ID: 22730670
    [No Abstract]   [Full Text] [Related]  

  • 4. [FLAG regimen in the treatment of refractory and relapsed acute myeloid leukemia].
    Shen ZX
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):1-2. PubMed ID: 21429391
    [No Abstract]   [Full Text] [Related]  

  • 5. Sequential reduced-intensity chemotherapy for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia with rare cytogenetic abnormalities transformed from Fanconi anemia.
    Inoue A; Mori A; Yamazaki S; Suzuki R; Takitani K; Tamai H
    Pediatr Int; 2018 Sep; 60(9):893-894. PubMed ID: 30255979
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effect of FLAG consolidation therapy on mobilization of autologous peripheral blood stem cells in patients with acute myelogenous leukemia].
    Li Q; Hong M; Qian SX; Zhang R; Sheng WY; Wu HX; Lu H; Qiu HX; Xu W; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1335-8. PubMed ID: 19840478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.
    Saini L; Brandwein J; Turner R; Larratt L; Hamilton M; Peters A; Wu C; Zhu N; Patterson JM; Bolster L; Mant M; Ritchie B; Liew E; Ghosh S; Sandhu I
    Eur J Haematol; 2016 Nov; 97(5):471-478. PubMed ID: 27028202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
    Kato K; Yoshida N; Matsumoto K; Matsuyama T
    Pediatr Blood Cancer; 2014 Apr; 61(4):712-6. PubMed ID: 24376191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia.
    Bug G; Koschmieder S; Krauter J; Heuser M; Thol F; Wiebe S; Hofmann WK; Klein SA; Wegener G; Göhring G; Heit W; Hoelzer D; Ganser A; Ottmann OG
    Ann Hematol; 2014 Feb; 93(2):193-202. PubMed ID: 23978944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of FLAG protocol in treatment of the first time induced non-remission acute myeloid leukemia].
    Wang SH; Yu L; Wang QS; Li HH; Zhao Y; Li F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1297-9. PubMed ID: 18088488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
    Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinic Outcome of FLAG Regimen treating Patients with Refractory and Relapse Acute Myeloid Leukemia].
    Wang LJ; Ding J; Zhu CY; Yang H; Wang HX; Jing Y; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):19-24. PubMed ID: 26913387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cord blood transplantation for acute myelogenous leukemia using a conditioning regimen consisting of granulocyte colony-stimulating factor-combined high-dose cytarabine, fludarabine, and total body irradiation.
    Tomonari A; Takahashi S; Ooi J; Nakaoka T; Takasugi K; Uchiyama M; Tsukada N; Konuma T; Iseki T; Tojo A; Asano S
    Eur J Haematol; 2006 Jul; 77(1):46-50. PubMed ID: 16573743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
    De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
    Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.
    Krejci M; Doubek M; Dusek J; Brychtova Y; Racil Z; Navratil M; Tomiska M; Horky O; Pospisilova S; Mayer J
    Ann Hematol; 2013 Oct; 92(10):1397-403. PubMed ID: 23728608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
    Ferrara F; Izzo T; Criscuolo C; Riccardi C; Celentano M; Mele G
    Am J Hematol; 2010 Sep; 85(9):687-90. PubMed ID: 20652967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
    Pastore D; Specchia G; Carluccio P; Liso A; Mestice A; Rizzi R; Greco G; Buquicchio C; Liso V
    Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous stem cell transplantation for advanced acute myeloid leukemia.
    Linker CA; Damon LE; Ries CA; Navarro WA; Case D; Wolf JL
    Bone Marrow Transplant; 2002 Feb; 29(4):297-301. PubMed ID: 11896426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
    Quarello P; Berger M; Rivetti E; Galletto C; Masetti R; Manicone R; Barisone E; Pession A; Fagioli F
    J Pediatr Hematol Oncol; 2012 Apr; 34(3):208-16. PubMed ID: 22395219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia.
    Aldoss I; Ji L; Haider M; Pullarkat V
    Acta Haematol; 2014; 131(4):202-7. PubMed ID: 24296475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.